Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?

Author： Aragon-Ching Jeanny B  

Publisher： Future Medicine

ISSN： 1479-6694

Source： Future Oncology, Vol.9, Iss.5, 2013-05, pp. : 619-622

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of enzalutamide in the treatment of castration-resistant prostate cancer

By Rawlinson Alex   Mohammed Aza   Miller Marek   Kunkler Roger  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1073-1081

Future Medicine

Access to resources Recommend Favorite

Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1040-1045

Bentham Science Publishers

Access to resources Recommend Favorite

TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer

By Oudard Stephane  

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 497-506

Future Medicine

Access to resources Recommend Favorite

Novel strategies in the treatment of castration-resistant prostate cancer (Review)

By          

International Journal of Oncology, Vol. 40, Iss. 5, 2012-01 ,pp. : 1313-1320

Spandidos Publications

Access to resources Recommend Favorite

Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature

By Moul Judd W.   Dawson Nancy  

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite